Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 0.21 is 107% above its 5-year average of -3.12, near the high end of its 5-year range (-5.66–0.21).
132.56% above its 12-month average of -0.65.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.11.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 22 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:35:37.877Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
0.21
EARNINGS PER SHARE (EPS) AVG TTM
-0.65
EARNINGS PER SHARE (EPS) AVG 3Y
-2.68
EARNINGS PER SHARE (EPS) AVG 5Y
-3.12
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+132.56%
CURRENT VS 3Y AVG
+107.83%
CURRENT VS 5Y AVG
+106.74%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Arcutis Biotherapeutics, Inc.
Market Cap
$3.09B
Earnings Per Share (EPS)
0.21
TTM Avg
-0.65
3Y Avg
-2.68
5Y Avg
-3.12
Market Cap
$3.09B
Earnings Per Share (EPS)
-1.64
TTM Avg
-1.86
3Y Avg
-2.94
5Y Avg
-3.21
Market Cap
$3.09B
Earnings Per Share (EPS)
-1.41
TTM Avg
-2.98
3Y Avg
-2.05
5Y Avg
-1.75
Market Cap
$3.13B
Earnings Per Share (EPS)
-2.84
TTM Avg
-2.77
3Y Avg
-2.30
5Y Avg
-1.82
Market Cap
$2.89B
Earnings Per Share (EPS)
-3.33
TTM Avg
-3.42
3Y Avg
-3.51
5Y Avg
-3.03
Market Cap
$2.82B
Earnings Per Share (EPS)
3.86
TTM Avg
3.33
3Y Avg
1.17
5Y Avg
0.32
Market Cap
$3.42B
Earnings Per Share (EPS)
N/A
TTM Avg
-87.94
3Y Avg
-87.94
5Y Avg
-87.94
Market Cap
$2.79B
Earnings Per Share (EPS)
0.21
TTM Avg
-0.59
3Y Avg
-0.72
5Y Avg
-0.48
Market Cap
$3.42B
Earnings Per Share (EPS)
-1.17
TTM Avg
-1.00
3Y Avg
-1.15
5Y Avg
-1.50
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | $3.09B | 0.21 | -0.65 | -2.68 | -3.12 |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.09B | -1.64 | -1.86 | -2.94 | -3.21 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | -1.41 | -2.98 | -2.05 | -1.75 |
| Denali Therapeutics Inc. (DNLI)vs › | $3.13B | -2.84 | -2.77 | -2.30 | -1.82 |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.89B | -3.33 | -3.42 | -3.51 | -3.03 |
| TransMedics Group, Inc. (TMDX)vs › | $2.82B | 3.86 | 3.33 | 1.17 | 0.32 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.42B | N/A | -87.94 | -87.94 | -87.94 |
| AtriCure, Inc. (ATRC)vs › | $2.79B | 0.21 | -0.59 | -0.72 | -0.48 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.42B | -1.17 | -1.00 | -1.15 | -1.50 |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.75B | -2.40 | -2.12 | -1.52 | -1.52 |
Trailing EPS (TTM)
$0.21
Forward EPS (Est.)
$0.50
P/E Ratio
118.4
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.13 |
| 2024-12-31 | -1.16 |
| 2023-12-31 | -3.78 |
| 2022-12-31 | -5.66 |
| 2021-12-31 | -4.17 |
| 2020-12-31 | -3.80 |
| 2019-12-31 | -1.10 |
| 2018-12-31 | -0.53 |
| 2017-12-31 | -4.71 |
